Literature DB >> 536837

Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma.

S V Hilts, D Hellman, J Anderson, J Woolfenden, J Van Antwerp, D Patton.   

Abstract

Exogenous triiodothyronine (T3) was substituted for levothyroxin or desiccated thyroid in 13 athyrotic patients previously treated for papillary, follicular, or mixed papillary-follicular carcinoma of the thyroid. After 4 weeks T3 therapy was discontinued and serial determinations of plasma thyroid stimulating hormone (TSH) concentrations were made. A roughly exponential rise in TSH values, corresponding to a doubling time of 2 days, was observed until a level of 40 microIU/ml was reached, after which the curve passed through a maximum at 20 days. The mean time required for a level of 50 microIU/ml was 11 days, and this time is suggested for TSH determination before I-131 imaging of patients with thyroid cancer. Plasma TSH values in eight patients following "total" thyroidectomy showed a much slower and more variable rise, with a mean doubling time of 7.6 days. Weekly TSH levels beginning at 15 days will provide a rational basis for I-131 imaging in this group, in whom a longer period of hypothyroidism will be required before imaging and therapy. Adherence to these protocols should minimize the duration of hypothyroidism in patients undergoing I-131 treatment of thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 536837

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Age and the thyrotropin response to hypothyroxinemia.

Authors:  Rebecca Over; Sonia Mannan; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

2.  In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.

Authors:  Laticia A Valle; Revital L Gorodeski Baskin; Kyle Porter; Jennifer A Sipos; Raheela Khawaja; Matthew D Ringel; Richard T Kloos
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

Review 3.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

4.  TSH regulation dynamics in central and extreme primary hypothyroidism.

Authors:  Marisa C Eisenberg; Ferruccio Santini; Alessandro Marsili; Aldo Pinchera; Joseph J DiStefano
Journal:  Thyroid       Date:  2010-11       Impact factor: 6.568

Review 5.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

6.  Simulation of post-thyroidectomy treatment alternatives for triiodothyronine or thyroxine replacement in pediatric thyroid cancer patients.

Authors:  Rotem Ben-Shachar; Marisa Eisenberg; Stephen A Huang; Joseph J DiStefano
Journal:  Thyroid       Date:  2012-05-11       Impact factor: 6.568

7.  Theophylline increases the uptake of radioiodine by mouse thyroid.

Authors:  Jong Min Lee; Patrizio Caturegli; Paul W Ladenson
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.